Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025)

Arcturus Therapeutics Holdings has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $4.2 million in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 68.36% year-over-year to $4.2 million; the trailing twelve-month figure through Sep 2025 stood at $4.2 million (down 68.36% YoY), and the FY2024 full-year result was $12.6 million, down 70.34% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $4.2 million, down from $8.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $42.5 million in Q4 2023, with the low at $4.2 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $15.2 million across 5 years, with a median of $11.3 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue soared 709.25% — and 2024, when it sank 70.34%.
• Arcturus Therapeutics Holdings' Non-Current Deffered Revenue stood at $19.9 million in 2021, then grew by 0.7% to $20.1 million in 2022, then surged by 111.73% to $42.5 million in 2023, then slumped by 70.34% to $12.6 million in 2024, then tumbled by 66.52% to $4.2 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $4.2 million (Q3 2025), $8.8 million (Q2 2025), and $9.6 million (Q1 2025), per Business Quant data.